Psychedelics and treatment-resistant depression: what the trials show
When standard antidepressants keep failing, psilocybin and ketamine are producing striking results in trials, sometimes after a single dose. Here's the evidence, and the caveats.
For roughly a third of people with depression, the usual antidepressants don't work. That is called treatment-resistant depression. It's one of the hardest problems in mental health, and it's where psychedelic research has drawn the most attention.
What the trials show
Ketamine, and its FDA-approved nasal form esketamine, can lift severe, treatment-resistant depression within hours to days, a speed no traditional antidepressant matches. Psilocybin (the compound in "magic mushrooms") has, in controlled phase 2 trials with therapy, produced rapid and sometimes lasting reductions in depression after just one or two dosing sessions. It holds an FDA "breakthrough therapy" designation.
Why it might work
Rather than nudging serotonin day by day, these compounds appear to trigger a burst of neuroplasticity: a temporary window in which the brain can form new connections. Paired with therapy, that window may let deeply worn patterns of thought loosen and reorganise.
The essential caveats
These effects come from supervised clinical settings with screening, preparation, and psychological support, not from taking a substance alone. Psilocybin remains investigational and, in most places, illegal outside trials. Set, setting, dose, and after-care all matter enormously.
Mura is educational only. We do not supply, prescribe, or recommend any substance. If you're struggling with depression, talk to a doctor about evidence-based options.
This article is for general information and is not a substitute for professional care. If you are in crisis or thinking about harming yourself, please contact your local emergency services or a crisis line. See crisis lines.